ROIV

Roivant Sciences Ltd
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$26.12B
P/E Ratio
EPS
$-0.54
Beta
1.11
52W High
$36.62
52W Low
$10.90
50-Day MA
$30.30
200-Day MA
$24.69
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Roivant Sciences Ltd

Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing the drug development and commercialization landscape through its unique business model and advanced technologies. The company boasts a robust pipeline that targets significant unmet medical needs across neurology, immunology, and rare diseases, positioning itself to efficiently navigate the complexities of drug development while minimizing costs. Led by a seasoned team and supported by strategic partnerships, Roivant aims to deliver both financial growth and enhanced patient outcomes, making it a compelling opportunity for institutional investors.

Official WebsiteUSAFY End: March

Fundamentals

Revenue (TTM)$8.26M
Gross Profit (TTM)$-673.94M
EBITDA$-1.28B
Operating Margin-14675.00%
Return on Equity-7.59%
Return on Assets-14.30%
Revenue/Share (TTM)$0.01
Book Value$6.29
Price-to-Book5.58
Price-to-Sales (TTM)3161.83
EV/Revenue2553.36
EV/EBITDA0.74
Quarterly Earnings Growth (YoY)-96.10%
Quarterly Revenue Growth (YoY)-66.70%
Shares Outstanding$719.27M
Float$563.99M
% Insiders23.39%
% Institutions75.90%

Historical Volatility

HV 10-Day
30.17%
HV 20-Day
29.61%
HV 30-Day
32.83%
HV 60-Day
43.25%
HV Rank
46.0%

Volatility is currently contracting

Analyst Ratings

Consensus ($39.38 target)
2
Strong Buy
10
Buy
1
Hold

Latest News

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

Seeking Alpha5/21/2026Positive
Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.

MarketBeat5/20/2026Neutral
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update.

GlobeNewsWire5/11/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026